Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more
Gilead Sciences is a biopharmaceutical leader best known for its HIV franchise, anchored by Biktarvy and Descovy, alongside a growing oncology and inflammation portfolio. This third-quarter report carries outsized weight because it tests whether the company can sustain durable growth beyond its mature HIV base. Investors are watching closely for momentum in newer products such as Trodelvy and Livdelzi, as well as the trajectory of HIV prevention. The quarter also arrived amid rising scrutiny of drug pricing, with the Centers for Medicare and Medicaid Services having finalized a Maximum Fair Price for Biktarvy that takes effect in 2028. Strong execution here offers a clearer read on Gilead's long-term diversification story.
For the third quarter of 2026, ended September 30, Gilead reported total revenue of $8.3 billion, a 6.8% increase from $7.77 billion a year earlier and above the roughly $7.81 billion Wall Street consensus. Product sales rose 13% to $8.29 billion, and excluding the COVID-19 treatment Veklury, product sales climbed 16% year over year. GAAP diluted EPS declined to $1.94 from $2.43, reflecting net losses from equity securities and higher operating costs, while non-GAAP diluted EPS rose 3% to $2.55 from $2.47.
The HIV franchise grew 18% to about $6.2 billion, with prevention sales nearly doubling. Biktarvy sales were roughly flat at about $4.1 billion, while Trodelvy sales rose 42% to an approximately $2 billion annual run rate. Product gross margin improved to 81.0% from 78.6%. Gilead raised full-year 2026 product sales guidance to $31.0 billion to $31.3 billion, though it widened its non-GAAP EPS outlook to a loss of $1.20 to $0.85 per share, driven largely by acquisition-related and other non-cash items.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Gilead, the AI Screener can streamline the search for comparable setups across the healthcare sector.
Gilead shares ended the regular session up 4.0% at $165.61 ahead of the release, then added roughly 1.8% in after-hours trading as investors digested the top- and bottom-line beats. The market appeared to reward the 6.3% revenue beat and the 16.2% non-GAAP EPS beat, as well as the upward revision to full-year product sales guidance. Still, sentiment remains tempered by the wider full-year non-GAAP loss forecast and the near-flat performance of Biktarvy, the company's single largest product. Net-net, the reaction suggests investors are focusing on the accelerating base-business growth rather than the near-term accounting headwinds.
Looking ahead, investors will be watching several catalysts tied to Gilead's diversification strategy. The company expects to file its investigational once-weekly oral HIV regimen, ISL/LEN, before year-end, and a potential approval decision for the cell therapy anito-cel is expected around the end of 2026. These pipeline milestones could meaningfully shape the company's longer-term growth narrative beyond Biktarvy.
In inflammation, Gilead plans to advance emvistegrast into Phase 3 studies for ulcerative colitis in 2027, backed by positive Phase 2 data. The company has also broadened its pipeline through acquisitions, including an oral IL-23 receptor inhibitor program, signaling continued investment in a third strategic therapeutic area alongside HIV and oncology.
On the policy front, the finalized Maximum Fair Price for Biktarvy under Medicare will begin affecting revenue on January 1, 2028, creating a medium-term headwind to monitor. Meanwhile, investors should track whether HIV prevention products such as Yeztugo and Descovy for PrEP (pre-exposure prophylaxis) sustain their rapid uptake, and whether Trodelvy maintains its momentum across breast cancer indications. Margin trends and the pace of operating-expense growth will also remain important signals of disciplined execution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor